Indane PD-L1 Inhibitors for Durable Checkpoint Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative small molecules as inhibitors of PD-L1 that offer advantages in oral administration, stability, bioavailability, therapeutic index, and toxicity compared to existing PD-1 pathway inhibitors.
Innovation Solution
Development of compounds having Formula (I) or (II) or their pharmaceutically acceptable salts, solvates, or hydrates, which can modulate the PD-1/PD-L1 pathway for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PD-1 or PD-L1 inhibitors are used, then immune checkpoint inhibition is achieved, but resistance develops limiting clinical efficacy
Solution Approach 1:
The invention segments the immune checkpoint inhibition mechanism by introducing a bivalent molecule that simultaneously binds to both PD-1 and PD-L1, rather than using monovalent inhibitors that target only one antigen. This segmentation approach allows the compound to engage multiple binding sites and prevent ligand-independent dimerization, thereby overcoming resistance mechanisms that limit the duration of response to single-antigen inhibitors.
Solution Approach 2:
The invention employs a composite molecular structure comprising a first indane ring system and a second indane ring system connected by a linker, where each indane system contains specific substituents (including heteroaryl groups, hydroxyl groups, and amino groups). This composite structure enables simultaneous interaction with both PD-1 and PD-L1 binding sites, creating a more robust and durable immune checkpoint inhibition that overcomes resistance to existing therapies.
2Reliability
If monovalent PD-1 or PD-L1 inhibitors are used, then immune checkpoint blockade is achieved, but ligand-independent dimerization occurs reducing efficacy
Solution Approach 1:
The bivalent indane compound acts as an intermediary that bridges both PD-1 and PD-L1 antigens simultaneously, preventing their ligand-independent dimerization. By occupying both binding sites with a single molecular entity, the compound intermediates the interaction between the two antigens and blocks the harmful dimerization event that would otherwise occur with monovalent inhibitors.
Solution Approach 2:
The invention changes the valency parameter of the inhibitor from monovalent to bivalent, fundamentally altering the binding mechanism. This parameter change transforms the inhibition strategy from blocking a single antigen-antibody interface to simultaneously engaging both PD-1 and PD-L1, thereby preventing dimerization and enhancing the reliability of immune checkpoint blockade.
3Reliability
If conventional inhibitor structures are used, then PD-1/PD-L1 binding is achieved, but resistance limits therapeutic response duration
Solution Approach 1:
The bivalent indane compound introduces dynamic engagement with both PD-1 and PD-L1 antigens simultaneously, creating a more stable and prolonged inhibitory effect. The molecular structure is designed to maintain concurrent binding to both antigens, dynamically preventing receptor activation and ligand-independent dimerization, thereby extending the duration of therapeutic response beyond what is achievable with static monovalent inhibitors.
Data Source
AI summary
Compounds represented by Formula (I) or (II) are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a', R2b', R2c', R3', R4', R5', R6a', R6b', Y, Y', and the subscripts m and n are as defined herein.